OncoNov delivers daily updates on cancer research, diagnostics, clinical trials, and treatments, providing clinicians and patients with the latest breakthroughs.
The FDA has approved SimpleScreen CRC, a blood-based screening test developed by Freenome, for average-risk adults aged 45 and older. The test detects cell-free DNA linked to colorectal cancer, and...
The phase 2 CHIMERA trial is evaluating whether adding pembrolizumab to standard chemotherapy before and after surgery can improve outcomes for patients with resectable pleural mesothelioma. About 40...
Updated results from the phase 1a FIT-001 trial show that darlifarnib (KO-2806) combined with cabozantinib produced encouraging results in patients with advanced clear cell renal cell carcinoma...
A phase 3 study of cretostimogene grenadenorepvec showed encouraging results in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). The...
Updated results from the phase 2 J201 study show that safusidenib continues to demonstrate promising long-term activity in patients with treatment-naive grade 2 IDH1-mutant glioma. After a median...
Daraxonrasib (RMC-6236) has been accepted by the FDA for review as a treatment for previously treated metastatic pancreatic ductal adenocarcinoma (PDAC). The oral drug targets multiple RAS mutations...
Results from the phase 1a/b TRAVERSE trial suggest that ALLO-316, an off-the-shelf CAR T-cell therapy targeting CD70, may be a promising treatment for patients with advanced clear cell renal cell...
The final 10-year results from the phase 3 RELEVANCE trial show that the chemotherapy-free combination of lenalidomide plus rituximab (R²) provides long-term outcomes similar to standard...
Results from the phase 2 KEYPAD trial suggest that combining pembrolizumab with denosumab may benefit patients with advanced clear-cell renal cell carcinoma (ccRCC) whose cancer progressed after...
